Achillion Pharmaceuticals, Inc. Achillion Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its unaudited financial results for the second quarter ended June 30, 2017.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its unaudited financial results for the first quarter ended March 31, 2017.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has Canaccord worried after releasing 2017 financial guidance yesterday morning that came up short of already subdued expectations. …
Piper Jaffray analyst Charles Duncan is out with a research note on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), previewing the drug maker’s upcoming earnings announcement, as well as …
Needham analyst Alan Carr is out with a mixed research report today on biotech players Gilead Sciences, Inc. (NASDAQ:GILD) and ACADIA Pharmaceuticals Inc.
As earnings season rolls to the foreground and key biotech players like Gilead Sciences, Inc. (NASDAQ:GILD), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), ACADIA Pharmaceuticals Inc.
Cowen analyst Ritu Baral weighs in today on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after the drug maker provided an update focusing on the ongoing launch of …
J.P.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares were shooting as if out of a canon on a 20% upturn this morning thanks to positive top-line …
